![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1424322
¼¼°è ÀڱðæºÎ ÀÌÇü¼ºÁõ ½ÃÀå : Áø´Ü À¯Çüº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº°Cervical Dysplasia Market, By Diagnosis Type (Diagnosis Test and Diagnostic Device ), By End User, By Geography |
ÀڱðæºÎ ÀÌÇü¼ºÁõ ½ÃÀå ±Ô¸ð´Â 2023³â 6¾ï 7,500¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í 2030³â 11¾ï 540¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 7.3%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.
º¸°í ¹üÀ§ | º¸°í¼ ¼¼ºÎÁ¤º¸ | ||
---|---|---|---|
±âÁسâ | 2022³â | 2023/2024³â ½ÃÀå ±Ô¸ð | 6¾ï 7,500¸¸ ´Þ·¯ |
½ÇÀû µ¥ÀÌÅÍ | 2018³â-2021³â | ¿¹Ãø ±â°£ | 2023-2030 |
¿¹Ãø±â°£ 2023³â/2024³â-2030³â/2031³â º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR): | 7.30% | 2030/2031³â ±Ý¾× ¿¹Ãø | 11¾ï 540¸¸ ´Þ·¯ |
ÀڱðæºÎ ÀÌÇü¼ºÁõÀº ÀÚ±ÃÀÇ ÀÔ±¸ÀÎ Àڱà °æºÎÀÇ ³»º®À» ±¸¼ºÇÏ´Â ¼¼Æ÷ÀÇ Àü¾Ï¼º º¯ÈÀÔ´Ï´Ù. ÀÌ·¯ÇÑ º¯È´Â °ñ¹Ý °Ë»ç Áß¿¡ Àڱà °æºÎ¿¡¼ äÃëµÇ´Â ¼¼Æ÷ »ùÇÃÀÇ Çö¹Ì°æ ºÐ¼®¿¡ ÀÇÇØ °ËÃâµË´Ï´Ù. ÆíÆò »óÇdz» º´º¯Àº Àڱà °æºÎ¿¡¼ äÃëÇÑ ¼¼Æ÷ÀÇ µµ¸» Ç¥º»¿¡¼ °üÂûµÇ´Â ÀڱðæºÎ ÀÌÇü¼ºÁõÀ» ÁöĪÇÏ´Â º´¸®ÇÐ ¿ë¾îÀÔ´Ï´Ù. ÀڱðæºÎ ÀÌÇü¼ºÁõÀº ÀÎÀ¯µÎÁ¾ ¹ÙÀÌ·¯½º(HPV)ÀÇ °¨¿°¿¡ ÀÇÇØ ¹ß»ýÇÕ´Ï´Ù. HPV´Â ¼ºÀû Á¢ÃËÀ¸·Î °¨¿°µÇ´Â ¸Å¿ì ÈçÇÑ °¨¿°ÀÔ´Ï´Ù. »õ·Î¿î HPV °¨¿°ÀÇ ´ëºÎºÐÀº ÀþÀº(15-25 ¼¼) ¿©¼º¿¡°Ô ¹ß»ýÇÕ´Ï´Ù. ´ëºÎºÐÀÇ HPV °¨¿°Àº Áõ»óÀ» ³ªÅ¸³»Áö ¾ÊÀ¸¸ç ÀÚ¿¬ÀûÀ¸·Î Ä¡À¯µË´Ï´Ù.
ÁÖ¿ä ½ÃÀå ±â¾÷¿¡ ÀÇÇÑ À¯±âÀû Àü·« Áõ°¡´Â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 3¿ù 1ÀÏ, °¨¿°, ¾Ï, HPV °ü·Ã ÁúȯÀÇ Ä¡·á ¹× ¿¹¹æÀ» À§ÇØ Á¤¹ÐÇÏ°Ô ¼³°èµÈ µ¥¿Á½Ã¸®º¸ ÇÙ»ê(DNA) ÀǾàǰÀÇ »ó½Ã¿¡ ÁÖ·ÂÇÏ´Â »ý¸í°øÇбâ¾÷ÀÎ À̳ëºñ¿À´Â REVEAL 1 ½ÃÇèÀÇ Æò°¡ °¡´ÉÇÑ ÇÇÇèÀÚ ¸ðµÎ¿¡ ÀÖ¾î¼ ÁÖ¿ä Æò°¡ Ç׸ñ°ú ºÎÂ÷ Æò°¡ Ç׸ñÀ» ´Þ¼ºÇß´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. º» ½ÃÇèÀº HPV-16/18°ú °ü·ÃµÈ ÀڱðæºÎ °í¾Ç¼ºµµ ÆíÆò»óÇdz» º´º¯(HSIL)¿¡ ´ëÇÑ VGX-3100ÀÇ ¾ÈÀü¼º, ³»¾à¼º, È¿´ÉÀ» ´ç»ç µ¶ÀÚÀûÀÎ CELLECTRA 5PSP ÀåÄ¡¸¦ »ç¿ëÇÏ¿© Æò°¡, ÇöÀç ÁøÇà ÁßÀÎ µÎ °¡Áö Áß¿äÇÑ ¹«ÀÛÀ§È ÀÌÁß ¸Í°Ë ´Ù ½Ã¼³ À§¾à ´ëÁ¶ 3 »ó ½ÃÇè Áß ÇϳªÀÔ´Ï´Ù.
The Cervical Dysplasia Market size is expected to reach US$ 1,105.4 Mn by 2030, from US$ 675 Mn in 2023, exhibiting a compound annual growth rate (CAGR) of 7.3% during the forecast period.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2022 | Market Size in 2023/2024: | US$ 675 Mn |
Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
Forecast Period 2023/2024 to 2030/2031 CAGR: | 7.30% | 2030/2031 Value Projection: | US$ 1,105.4 Mn |
Cervical dysplasia is precancerous changes of the cells that make up the lining of the cervix, the opening to the womb (uterus). These changes are detected by microscopic analysis of cell samples which are taken from the cervix during a pelvic exam. Squamous intraepithelial lesion is the pathology term that is used to refer to cervical dysplasia which is observed in smears of cells taken from the cervix. Cervical dysplasia is caused by infection with the human papillomavirus (HPV). HPV is a very common infection that is transmitted through sexual contact. Most new HPV infections occur in young (ages 15-25) women. Most HPV infections do not produce any symptoms and resolve spontaneously.
Increasing organic strategies by the key market players is expected to drive the market growth over the forecast period. For instance, on March 1, 2021, INOVIO, a biotechnology company focused on bringing to market precisely designed deoxyribonucleic acid (DNA)medicines to treat and protect people from infectious diseases, cancer and HPV-associated diseases, announced that it met primary and secondary endpoints among all evaluable subjects for the REVEAL 1 trial. This trial is one of two ongoing pivotal, randomized, double-blind, multi-center, placebo-controlled, Phase 3 trials evaluating the safety, tolerability, and efficacy of VGX-3100 to treat HPV-16/18-associated cervical high-grade squamous intraepithelial lesions (HSIL) using the company's proprietary CELLECTRA 5PSP device.
Cervical Dysplasia Market Detailed Segmentation: